The safety of an adenosine A1-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: Findings from PROTECT

Drug Safety

Volumn 35, Issue 3, 2012, Pages 233-244

  Teerlink, John R ^a   Iragui, Vicente J ^b   Mohr, Jay P ^c   Carson, Peter E ^d   Hauptman, Paul J ^e   Lovett, David H ^a   Miller, Alan B ^f   Piña, Ileana L ^g   Thomson, Scott ^b   Varosy, Paul D ^h   Zile, Michael R ⁱ   Cleland, John G F ^j   Givertz, Michael M ^k   Metra, Marco ^l   Ponikowski, Piotr ^m   Voors, Adriaan A ⁿ   Davison, Beth A ^o   Cotter, Gad ^o   Wolko, Denise ^p   DeLucca, Paul ^p   Salerno, Christina M ^p   Mansoor, George A ^p   Dittrich, Howard ^p   O'Connor, Christopher M ^q   Massie, Barry M ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j UNIVERSITY OF HULL   (United Kingdom)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l UNIVERSITY OF BRESCIA   (Italy)

^m WROCLAW MEDICAL UNIVERSITY   (Poland)

ⁿ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^o Momentum Research Inc   (United States)

^p MERCK RESEARCH LABORATORIES   (United States)

^q DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Acute heart failure; Adenosine A1 receptor antagonists; Myocardial infarction; Myocardial ischaemia; Renal impairment; Rolofylline

Indexed keywords

PLACEBO; ROLOFYLLINE; 1,3-DIPROPYL-8-(3-NORADAMANTYL)XANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; XANTHINE DERIVATIVE;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; BRADYCARDIA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEIZURE; STROKE; SUPRAVENTRICULAR TACHYCARDIA; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; MIDDLE AGED; RISK FACTOR; TIME;

ACUTE DISEASE; ADENOSINE A1 RECEPTOR ANTAGONISTS; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RISK FACTORS; STROKE; TIME FACTORS; XANTHINES;

EID: 84857176387     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11594680-000000000-00000     Document Type: Article

References (26)

1. Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol 2009; 193: 25-58
2. Boison D. Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 2005 Feb; 11 (1): 25-36 (Pubitemid 40223088)
3. Cotter G, Dittrich HC, Weatherley BD, et al. The PROTECT pilot study: a randomized, placebo-controlled, dosefinding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008 Oct; 14 (8): 631-40
4. Weatherley BD, Cotter G, Dittrich HC, et al. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J Card Fail 2010 Jan; 16 (1): 25-35
5. Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363 (15): 1419-28
6. Kunitz SC, Gross CR, Heyman A, et al. The pilot Stroke Data Bank: definition, design, and data. Stroke 1984 Jul-Aug; 15 (4): 740-6 (Pubitemid 14090257)
7. Adams Jr HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993 Jan; 24 (1): 35-41 (Pubitemid 23014379)
8. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985 Apr-Jun; 4 (2): 213-26 (Pubitemid 15055349)
9. Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIRAMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006 Jan; 8 (1): 105-10 (Pubitemid 43012109)
10. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003 Mar 19; 41 (6): 997-1003 (Pubitemid 36315544)
11. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA2002Mar 27; 287 (12): 1531-40
12. Fredholm BB, Chen JF, Masino SA, et al. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 2005; 45: 385-412 (Pubitemid 40261811)
13. Boison D. The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 2008 Mar; 84 (3): 249-62
14. Ribeiro JA. What can adenosine neuromodulation do for neuroprotection? Curr Drug Targets CNS Neurol Disord 2005 Aug; 4 (4): 325-9 (Pubitemid 41086753)
15. Givertz MM, Massie BM, Fields TK, et al. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007 Oct 16; 50 (16): 1551-60 (Pubitemid 47532320)
16. Dittrich HC, Gupta DK, Hack TC, et al. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 2007 Oct; 13 (8): 609-17 (Pubitemid 47513547)
17. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998 Apr 22-29; 279 (16): 1265-72
18. Sherman DG, Dyken Jr ML, Gent M, et al. Antithrombotic therapy for cerebrovascular disorders: an update. Chest 1995 Oct; 108 (4 Suppl.): 444-56S
19. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl JMed 2001 Nov 15; 345 (20): 1444-51
20. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007 Nov 7; 298 (17): 2009-19 (Pubitemid 350074798)
21. Greenberg B, Thomas I, Banish D, et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol 2007 Aug 14; 50 (7): 600-6 (Pubitemid 47198998)
22. Suzuki T, Hirata K, Elkind MS, et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). Am Heart J 2008 Aug; 156 (2): 405-10
23. Kitagawa H, Mori A, Shimada J, et al. Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats. Neurol Res 2002 Apr; 24 (3): 317-23 (Pubitemid 34275204)
24. Fantidis P. The role of intracellular 3'5'-cyclic adenosine monophosphate (cAMP) in atherosclerosis. Curr Vasc Pharmacol 2010 Jul; 8 (4): 464-72
25. Sebastiao AM, Ribeiro JA. Adenosine receptors and the central nervous system. Handb Exp Pharmacol 2009; 193: 471-534
26. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009; 193: 535-87